Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11557958 | 1.00 | CRBN (0.36) | CRBNTAS2R38 | |
| SCHEMBL11363509 | 0.80 | CYP2D6 (0.34) | CRBNTAS2R38 | |
| SCHEMBL11345209 | 0.78 | — | — | |
| SCHEMBL8353811 | 0.72 | GRIK1 (0.50) | — | |
| SCHEMBL14344224 | 0.72 | GRIK1 (0.50) | — | |
| SCHEMBL22769505 | 0.72 | GRIK1 (0.50) | — | |
| SCHEMBL9438438 | 0.71 | GRIK1 (0.48) | — | |
| SCHEMBL18057552 | 0.70 | ALDH1A1 (0.50) | — | |
| SCHEMBL18766394 | 0.70 | ALDH1A1 (0.38) | CRBNTAS2R38 | |
| SCHEMBL10404787 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010655-A1 | Stationary phases and a purification process using the stationary phases | MERCK & CO., INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1663275-A2 | STATIONARY PHASES AND A PURIFICATION PROCESS USING THE STATIONARY PHASES | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026323-A2 | STATIONARY PHASES AND A PURIFICATION PROCESS USING THE STATIONARY PHASES | MERCK & CO., INC. (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010655-A1 | Stationary phases and a purification process using the stationary phases | VIP, LPXN, PROKR1 | CRBN 4321/4885TAS2R38 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.